Published in Tissue Antigens on July 01, 1975
Association of HLA B8 with spontaneous resolution in sarcoidosis. Thorax (1981) 1.80
HLA antigens in sarcoidosis. Clin Exp Immunol (1977) 1.52
High prevalence of familial sarcoidosis in an Irish population. Thorax (1984) 1.20
HLA-B8 and erythema nodosum. Can Med Assoc J (1982) 0.80
Chromosome analysis in patients with sarcoidosis. Arch Dermatol Res (1980) 0.75
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
HL-A antigens and diabetes mellitus. Lancet (1974) 4.42
HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens (1974) 4.41
The relation between survival and age at diagnosis in breast cancer. N Engl J Med (1986) 4.21
HLA and disease 1982--a survey. Immunol Rev (1983) 3.87
The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med (1989) 3.77
Parity, age at first childbirth, and risk of ovarian cancer. Lancet (1994) 3.48
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol (1995) 3.30
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Suggestion of linkage of a major locus for nonsyndromic orofacial cleft with F13A and tentative assignment to chromosome 6. Clin Genet (1987) 3.14
Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol (1997) 3.10
Linkage relationships of paraoxonase (PON) with other markers: indication of PON-cystic fibrosis synteny. Clin Genet (1985) 2.96
HL-A and disease associations--a survey. Transplant Rev (1975) 2.87
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet (1999) 2.85
Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A (1999) 2.83
Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group. Lancet (1997) 2.70
Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum (1999) 2.66
Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet (1973) 2.41
Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet (1995) 2.31
A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics (1994) 2.31
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
HLA and disease associations: detecting the strongest association. Tissue Antigens (1994) 2.22
Cancer risk in patients with diabetes mellitus. Cancer Causes Control (1991) 2.18
Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol (1998) 2.11
HL-A antigens and multiple sclerosis. Lancet (1972) 2.09
Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol (1989) 2.07
HLA-D region beta-chain DNA endonuclease fragments differ between HLA-DR identical healthy and insulin-dependent diabetic individuals. Nature (1983) 1.99
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer (1999) 1.98
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol (1988) 1.97
MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. Transplant Rev (1975) 1.97
Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet (1997) 1.92
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer (1998) 1.86
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis Rheum (1982) 1.83
HLA genotype distribution and genetic models of insulin-dependent diabetes mellitus. Ann Hum Genet (1981) 1.78
Genetics of HLA disease association. Annu Rev Genet (1981) 1.74
Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst (1999) 1.73
Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod (2006) 1.69
Human cell-mediated cytotoxicity against modified target cells is restricted by HLA. Nature (1977) 1.69
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst (1997) 1.68
Studies of the HLA system and insulin-dependent diabetes mellitus. Diabetes Care (1980) 1.63
Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol (2004) 1.62
Time trends in incidence rates of first hip fracture in the Uppsala Health Care Region, Sweden, 1965-1983. Am J Epidemiol (1989) 1.62
Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet (1998) 1.62
Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control (2000) 1.61
Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med (2001) 1.59
Effect of thapsigargin on cytoplasmic Ca2+ and proliferation of human lymphocytes in relation to AIDS. Biochim Biophys Acta (1988) 1.59
Nomenclature for factors of the HLA system, 2004. Tissue Antigens (2005) 1.57
Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet (1999) 1.53
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem (1986) 1.51
CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol (1998) 1.50
Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet (1994) 1.50
Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology (1999) 1.49
Risk of cancer in women receiving hormone replacement therapy. Int J Cancer (1989) 1.49
Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ (1998) 1.48
Fracture of the distal forearm as a forecaster of subsequent hip fracture: a population-based cohort study with 24 years of follow-up. Calcif Tissue Int (1993) 1.48
Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A (1997) 1.47
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens (2004) 1.47
Delayed density-dependence in a small-rodent population. Proc Biol Sci (1995) 1.46
The effect of female sex hormones on cancer survival. A register-based study in patients younger than 20 years at diagnosis. JAMA (1990) 1.45
Long-term trends in incidence of and mortality from acute myocardial infarction and stroke in women: Analyses of total first events and of deaths in the Uppsala Health Care Region, Sweden. Epidemiology (1996) 1.45
Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood (2001) 1.44
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43
HLA-D and -DR antigens in genetic analysis of insulin dependent diabetes mellitus. Diabetologia (1981) 1.43
An outbreak of listeriosis suspected to have been caused by rainbow trout. J Clin Microbiol (1997) 1.42
Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer (1997) 1.42
Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control (1999) 1.42
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol (1989) 1.41
Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences. Scand J Immunol (1988) 1.40
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol (1984) 1.40
Nomenclature for factors of the HLA system, 1998. Tissue Antigens (1999) 1.40
[Transplantation. Blood, bone marrow and solid organs]. Ugeskr Laeger (2000) 1.39
Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci U S A (1998) 1.38
Mammographic parenchymal patterns in women receiving noncontraceptive estrogen treatment. Am J Epidemiol (1989) 1.38
The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum (2000) 1.37
Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol (1988) 1.37